TEVA
NYSETeva Pharmaceutical Industries Limited
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Price$34.18+1.29 (+3.92%)
2026-03-042026-06-05
News · 26 weeks90+90%
2025-12-142026-06-07
Mix3690d
- Insider17(47%)
- Other11(31%)
- SEC Filings5(14%)
- Earnings3(8%)
Latest news
25 items- PRTeva Presents New Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets that Show Patient- and Caregiver-Reported Improvements in Huntington's Disease ChoreaNew real-world survey data reveal the daily impact of Huntington's disease (HD) chorea, with over 68% of patients reporting interference with social life or emotional wellbeing1 and up to 83% of caregivers noting impact on their own daily lives.2Following treatment with AUSTEDO or AUSTEDO XR, most patients (60-71%) reported improvement across multiple quality of life domains as a result of their improved movements.1 As a result of the patient's reduced chorea impact, most caregivers reported less impact to their daily lives.2These real-world findings reinforce Teva's commitment to advancing innovative treatment options that improve the lives of individuals living with HD chorea and their car
- INSIDEREVP, Global Operations Shields Matthew converted options into 16,195 units of Ordinary Shares and sold $532,330 worth of Ordinary Shares (16,195 units at $32.87) as part of a pre-agreed trading plan (SEC Form 4)4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)
- PRTeva Expands European biosimilars portfolio with launch of AHZANTIVE® (aflibercept) biosimilar to Eylea®AHZANTIVE® (aflibercept) is an EMA-approved biosimilar to Eylea® (aflibercept) with demonstrated similarity in efficacy, safety and immunogenicity to the reference product The launch expands Teva's biosimilars portfolio and presence in ophthalmology, in line with the Company's Pivot to Growth strategy Teva continues to broaden availability of biosimilars in Europe reinforcing the Company's commitment to improving patient access to biologic medicines TEL AVIV, Israel, June 04, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the launch of AHZANTIVE (aflibercept), a biosimilar to Eylea®, in Europe further strengthening the Company's growing
- PRTeva to Present at the Goldman Sachs Global Healthcare ConferencePARSIPPANY, N.J., and TEL AVIV, Israel, June 01, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will participate in a fireside chat at the Goldman Sachs Global Healthcare Conference on Monday, June 8, 2026. The fireside chat will begin at 8:00 A.M. Eastern Time. To access live webcasts of the presentations, please visit Teva's Investor Relations website at https://ir.tevapharm.com/Events-and-Presentations. Archived versions of the webcasts will be available within 24 hours after the end of the live discussion and will be accessible for up to 30 days. About Teva Teva Pharmaceutical Indust
- INSIDERSEC Form 4 filed by Director Zaks Tal Zvi4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)
- INSIDERSEC Form 4 filed by Director Satchi-Fainaro Ronit4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)
- INSIDERSEC Form 4 filed by Director Nisen Perry4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)
- INSIDERSEC Form 4 filed by Director Lieberman Gerald M4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)
- INSIDERSEC Form 4 filed by Director Elstein Amir4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)
- INSIDERSEC Form 4 filed by Director Crane Rosemary A4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)
- INSIDERSEC Form 4 filed by Director Lichtenstein Chen4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)
- INSIDERSEC Form 4 filed by Director Barer Sol J4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)
- INSIDERSEC Form 4 filed by Director Mignone Roberto4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)
- SECSEC Form 8-K filed by Teva Pharmaceutical Industries Limited8-K - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Filer)
- PRThe European Medicines Agency Accepts Teva's Marketing Authorization Application for Olanzapine Long-Acting Injectable (TEV-'749) for the Treatment of Schizophrenia in AdultsThe olanzapine long-acting injectable (TEV-'749) is designed to deliver the efficacy of olanzapine in a subcutaneous formulation1 administered every four weeks.If approved, TEV-‘749 could help fill a significant unmet need in available schizophrenia treatment options by addressing the lack of a viable long-acting olanzapine formulation.Teva is committed to advancing this innovative treatment option, strengthening its scientific leadership in complex neurological conditions as part of its Pivot to Growth strategy. TEL AVIV, Israel and PARIS, May 21, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE:AND) and Medincell
- INSIDEREVP, Business Development Lippman Evan sold $1,482,367 worth of Ordinary Shares (41,658 units at $35.58) as part of a pre-agreed trading plan and converted options into 85,849 units of Ordinary Shares (SEC Form 4) (for tax liability)4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)
- INSIDEREVP, Chief Financial Officer Kalif Eliyahu Sharon sold $5,457,375 worth of Ordinary Shares (153,251 units at $35.61) as part of a pre-agreed trading plan, decreasing direct ownership by 47% to 172,184 units (SEC Form 4)4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)
- PRFitch Upgrades Teva to Investment Grade Amid Pivot to Growth ExecutionTEL AVIV, Israel, May 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Fitch Ratings Agency ("Fitch") has raised the Company's corporate credit rating to Investment Grade BBB-, with a stable outlook, from BB+. "This strong endorsement, our third upgrade from Fitch in less than two years, underscores Teva's transformation journey and execution of its Pivot to Growth strategy, as well as shows confidence in our increasing financial flexibility" said Eli Kalif, Teva's Chief Financial Officer. Fitch has also upgraded its ratings on Teva's senior unsecured debt and credit facilities to BBB- from BB+. Fitch's report highlights Teva's
- PRTeva Study Finds Only 23% of Younger Adults with Mood Disorders and Tardive Dyskinesia (TD) Symptoms Are Formally Diagnosed with TD Despite Widespread ImpactNew analysis from the IMPACT-TD Registry confirms tardive dyskinesia (TD) causes a significant burden for most individuals with concomitant mood disorders, impacting their lives regardless of ageThe data shows that 85% of young adults with mood disorders living with TD movements, ages 18-29 (n=13), experience moderate to severe TD impact, yet only 23% received a formal diagnosis of TD, revealing a gap in disease identificationTeva is dedicated to advancing research and initiatives that deepen clinical understanding, identify diagnostic gaps and improve outcomes for patients with TD PARSIPPANY, N.J. and TEL AVIV, Israel, May 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affilia
- INSIDERChief Accounting Officer Weiss Amir sold $384,444 worth of Ordinary Shares (10,679 units at $36.00), decreasing direct ownership by 35% to 20,016 units (SEC Form 4)4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)
- INSIDEREVP, Europe Commercial Daniell Richard sold $1,062,000 worth of Ordinary Shares (30,000 units at $35.40), decreasing direct ownership by 35% to 55,755 units (SEC Form 4)4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)
- PRTeva to Present at the BofA Securities Health Care ConferencePARSIPPANY, N.J., and TEL AVIV, Israel, May 04, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Eric Hughes, Teva's EVP of Global R&D & Chief Medical Officer, will present at the BofA Securities Health Care Conference on Tuesday, May 12, 2026. The presentation will begin at 9:20 A.M. Pacific Time (12:20 P.M. Eastern Time). To access live webcasts of the presentations, please visit Teva's Investor Relations website at https://ir.tevapharm.com/Events-and-Presentations. Archived versions of the webcasts will be available within 24 hours after the end of the live discussion and will be accessible for up to 30 days. About Teva Teva Pha
- INSIDERSee "Remarks" Sabag Mark sold $5,045,118 worth of Ordinary Shares (144,180 units at $34.99), decreasing direct ownership by 64% to 80,760 units (SEC Form 4)4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)
- INSIDEREVP, U.S. Commercial Fox Christine sold $750,620 worth of Ordinary Shares (21,258 units at $35.31), decreasing direct ownership by 25% to 63,647 units (SEC Form 4)4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)
- PRTeva's 2025 Healthy Future Report Highlights Environmental and Access to Medicines Progress, Including Meeting All Sustainability-Linked Bond TargetsTeva exceeded all sustainability-linked bond targets, linking financial performance to expanded patient access to medicines and reduced environmental impact.Through its global access to medicines programs, Teva reached nearly 8 million people through product donations around the world.39% reduction in Teva's Scope 1 and 2 GHG emissions since 2019 and 32% reduction in Scope 3 GHG emissions since 2020—exceeding 25% reduction targets.More than 99% of active employees completed compliance and ethics training. Teva's generic medicines contributed $36.4 billion in savings for healthcare systems across 21 countries. TEL AVIV, Israel, April 30, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Indus
TEVA FAQ
6 questionsWhat does Teva Pharmaceutical Industries Limited do?
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology...Where does TEVA stock trade?
Teva Pharmaceutical Industries Limited (TEVA) is listed on NYSE.What sector and industry is TEVA in?
Teva Pharmaceutical Industries Limited operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about TEVA?
Teva Pharmaceutical Industries Limited has had 8 recent analyst actions on file. The most recent action was from Barclays: Overweight with a $3500.00 price target on 2025-12-09. Recent price targets range from $1400.00 to $3500.00.What companies are similar to TEVA?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare TEVA side-by-side with any of them on Quantisnow.How can I track TEVA on Quantisnow?
Quantisnow aggregates Teva Pharmaceutical Industries Limited's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TEVA to receive live email and push alerts on every new disclosure.